If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kg PDUFA target action date of January 30, 2027 September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its

Results presented at IMS 2026 show ZENBEXUS in combination with daratumumab and dexamethasone doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41.1% vs. 20.7%) Data reinforce the value of the ZENBEXUS-based triplet as an effective, easily administered treatment option for patients with relapsed or refractory multiple myeloma as early as first relapse Results simultaneously published in The Lancet Oncology Bristol Myers Squibb (N

The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases. Roche is doling out $70 million to pair up with Atavistik Bio in hopes of discovering new small molecule therapeutics against cardiovascular, renal and metabolic diseases, with an additional $1.9 billion in biobucks up for grabs. The Big Pharma is joining forces with the hematology-focused biotech to use its allosteric drug discovery platform, dubbed AMPS,

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the treatment of B-cell malignancies. Under the terms

First-in-class KRAS-payload leveraging synchronized EGFR inhibition Sept. 27, 2026 -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors. The first patient received the first dose in China on September 24, 2026. An Antibody-Targeted Therapy Conjugate (“ATTC”) enables tumor-specific activity of potent, ce

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell compon

New results suggest earlier treatment may increase the likelihood of long-term remission Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and disease control Sept. 25, 2026 -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, announced today new long-term follow-up data from the initial subgroup of cohort A in the Phase 2 C

This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's AI and robotics-driven drug discovery platform and its transition to a clinical-stage organization. Preclinical data demonstrate sub-nanomolar potency (< 1 nM) alongside a gut-to-blood exposure ratio exceeding 1,000:1, confining pharmacological activity to the gastrointestinal tract to limit systemic exposure. The candidate is the industry's firs

UK-based Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN biological foundation models and advance AI-designed therapies towards clinical development. S32 led the oversubscribed financing round. Investors included Catalio Capital Management, European Tech Collective, and Firebrand River Capital. Other backers were Nvidia, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. The company said the late

Based on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab) in combination with enfortumab vedotin (EV) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have declined cisplatin-based chemotherapy